Roberts W G, Delaat J, Nagane M, Huang S, Cavenee W K, Palade G E
Department of Cellular and Molecular Medicine, University of California-San Diego, La Jolla, USA.
Am J Pathol. 1998 Oct;153(4):1239-48. doi: 10.1016/S0002-9440(10)65668-4.
We have previously demonstrated that vascular endothelial growth factor-165 (VEGF), a tumor-secreted angiogenic factor, can acutely and chronically induce fenestrations in microvascular endothelium (Cancer Res 1997, 57:765-772). Because the morphology and function of microvascular endothelium differs from tissue to tissue, we undertook studies to examine whether the neovasculature in tumors also differed depending upon tumor location. Four tumor types implanted in the brain or subcutis in nude mice were studied: a murine rhabdomyosarcoma (M1S), a murine mammary carcinoma (EMT), and two human glioblastomas (U87 and U251). In addition, we studied Chinese hamster ovary cells stably transfected with human VEGF165. As previously reported, tumors grown in the subcutaneous space had a microvasculature that was fenestrated and had open endothelial gaps. The identical tumors when grown in the brain also had fenestrated endothelium and vessels with open endothelial gaps, but they were drastically reduced in occurrence. Open endothelial gaps were not seen in all tumors implanted in the brain (EMT and M1S), although fenestrated endothelium was always seen. VEGF and VEGF receptors were measured in tumors from both locations by immunoblotting and competitive polymerase chain reaction, respectively. VEGF amount was not significantly different between the tumor locations. Interestingly, total tumor vascular mRNA expression of both Flk-1 and Flt-1 was greater in tumor vessels derived from the brain compared with tumor vessels derived from subcutaneous tissues. These results demonstrate that the host microvascular environment determines the morphology and function of the tumor vasculature and that endothelia from different tissues vary in their ability to express the VEGF receptors given identical stimuli.
我们先前已经证明,血管内皮生长因子-165(VEGF),一种肿瘤分泌的血管生成因子,可急性和慢性诱导微血管内皮形成窗孔(《癌症研究》1997年,57:765 - 772)。由于微血管内皮的形态和功能因组织而异,我们进行了研究以检查肿瘤中的新生血管是否也因肿瘤位置不同而有所差异。研究了植入裸鼠脑内或皮下的四种肿瘤类型:一种鼠横纹肌肉瘤(M1S)、一种鼠乳腺癌(EMT)以及两种人胶质母细胞瘤(U87和U251)。此外,我们还研究了稳定转染人VEGF165的中国仓鼠卵巢细胞。如先前报道,生长在皮下空间的肿瘤具有有窗孔且内皮间隙开放的微血管系统。同样的肿瘤生长在脑内时也有有窗孔的内皮和内皮间隙开放的血管,但这种情况的发生率大幅降低。并非所有植入脑内的肿瘤(EMT和M1S)都可见内皮间隙开放,尽管总是能见到有窗孔的内皮。分别通过免疫印迹和竞争性聚合酶链反应测量了两个部位肿瘤中的VEGF和VEGF受体。肿瘤部位之间的VEGF量没有显著差异。有趣的是,与源自皮下组织的肿瘤血管相比,源自脑内的肿瘤血管中Flk-1和Flt-1的总肿瘤血管mRNA表达更高。这些结果表明,宿主微血管环境决定了肿瘤血管系统的形态和功能,并且在相同刺激下,不同组织的内皮表达VEGF受体的能力有所不同。